This workshop provides an opportunity to get an overview of translational nanobiomedicine research from the leading European experts. The overarching themes are interactions of nanoparticles with biological systems, applications of precision-guided nanosystems for imaging and more efficient therapies, and the relationship of nanotechnology with personalized medicine.
Targeted nanosystems for imaging and therapy
Spring workshop, Tartu (Estonia)
May 10-12, 2017
Venue: V-Spa Hotel and Conference Center, Riia 2, Tartu
Target audience : Graduate students , research staff
Free Registration at: http://registration.amarela.ee/spring-workshop/
Program and more information : Click Here
We report in Biomaterials development of a tumor-specific delivery system for the treatment of peritoneal carcinomatosis. We demonstrate that after intraperitoneal administration, pH-sensitive polymeric vesicles loaded with an anticancer drug paclitaxel and functionalized with the tumor penetrating peptide iRGD specifically accumulate in peritoneal tumors in mice and have higher antitumor activity than free paclitaxel or Abraxane (a nano-formulation currently used in the therapy of several types of carcinoma). Our findings suggest that iRGD polymersomes may potentially be translated to therapeutic interventions against peritoneal carcinomatosis.
This collaborative study was driven and coordinated by our senior researcher Lorena Simón-Gracia and carried out together with Prof. Giuseppe Battaglia’s lab in UC London (UK) and with Drs. Kazuki N Sugahara and Ramana Kotamraju and Prof. Erkki Ruoslahti at Sanford Burnham Prebys Medical Discovery Institute in La Jolla, Calif. (USA).
iRGD peptide conjugation potentiates intraperitoneal tumor delivery of paclitaxel with polymersomes Biomaterials. 2016 Jul 20;104:247-257.
Image: Homing of green fluorescent iRGD polymersomes in CT26 peritoneal tumor (Tu). Note that control organs (liver, Li; lung, Lu; spleen, Sp; kidney, Ki) and subcutaneous tumors (Tu s.c.) show minimal labeling.
This peptide can guide drugs and imaging agents to acute brain injuries and result in enhanced benefit. The peptide was identified by Aman Mann and Pablo Scodeller in the lab of Dr. Erkki Ruoslahti in collaboration with the cancer biology lab.
Link to the paper: Nature Communications
Image: The tiny peptide CAQK improves the delivery of imaging agents to acute brain injuries. (Luminiscence from porous silicon nanoparticles targeted with CAQK and control peptide CGGK in brain injuries)
Our article titled "Targeted Silver Nanoparticles for Ratiometric Cell Phenotyping" is well received. It has been chosen to the cover of the May issue of Nanoscale and the Atlas of Science has published a layman's summary about the work.
Artwork: Peter and Ryan Allen, UC Santa Barbara, USA.
Kadri Toome awarded the best poster prize on meeting of Finnish Peptide Society (Helsinki, August 2015)
Kadri Toome and Tambet Teesalu of the laboratory of Cancer Biology participated in the joint symposium of the Finnish Synthetic Chemistry Society, the Medicinal Chemistry Committee of the Finnish Pharmaceutical Society and the Finnish Peptide Society “Emerging targets and molecules in middle space” (Helsinki, Finland, August 24-27, 2015). Kadri’s poster “Development and in vivo validation of blood-brain barrier targeting peptides” (authors: Toome K, Säälik P, Willmore AM, Tarmo Mölder T, Sudakov A, Kõiv K, Nikonov A, Teesalu T) was awarded the best poster prize. Tambet presented an invited talk entitled „Tumor homing peptides v2.0: streamlined discovery and applications for targeted payload delivery”.
At the beginning of March a new member Maarja Haugas joined with the Lab of Cancer Biology. After ten years in Finland at the University of Helsinki, where she defended a PhD degree in developmental biology and veterinary anatomy in 2011 and continued as a postdoctoral researcher in developmental neurobiology, she has returned to beloved University of Tartu. She has background in molecular and developmental biology and in neuroscience, as well as know-how in histology.
Starting from 1st of February a new lab member has joined us. Pablo David Scodeller is from Argentina and he concluded his PhD studies in the University of Buenos Aires under the supervision of Dr. Ernesto Calvo. He then went on to work in the 'Chemistry of Nanomaterials' group led by Dr. Galo Soler Illia of Buenos Aires, under CONICET fellowship. For the last two years he's been working in the 'Vascular Mapping Laboratory' of Dr. Erkki Ruoslahti at Sanford-Burnham Medical research Institute, in La Jolla, USA. His main research interests are: Nanomedicine, Tumor microenvironment, drug penetration, drug delivery, adjuvants of oncolytic drugs. Phage display in vivo and in vitro. Neurodegenerative diseases and brain injuries. His main hobbies include: cogitations over beer, tango music, attending milongas, and the study of the Buenos Aires jargon called Lunfardo .
On 17th of September Kairit Šor joined Cancer Biology group as a executive administrative assistant. Her duties are taking care of grant financials (budgets, expenses etc) and overall office problems. Please do not hesitate to contact her with mentioned issues.
About her: she has more than 5 years of experience working in University of Tartu also as a project manager, has a BA in classical philology and soon to be graduate her master studies of philosophy of science.